AzTrials
AzTrials

Chronic Obstructive Pulmonary DiseaseCORSAINCT04628962

Raman Analysis of Saliva as Biomarker of COPD

An observational study of Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 5 sites in 4 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and chronic lung syndrome that causes accelerated lung function decline and death in the 20% of cases. Mostly, the non-adherence to therapy contributes to symptoms increase, mortality, inability and therapies failure, highly influencing the management… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Chronic Obstructive Pulmonary Disease
What is being tested?
Collection and Raman analysis of saliva for the database
Type of treatment
Surgery or procedure
How many people
250 participants
Where
5 sitesin 4 countries
Study dates
1 Feb 2022to 1 Jan 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study population will be recruited from the primary care clinic patients under treatment at IRCCS Fondazione Don Carlo Gnocchi ONLUS - Ospedale Santa Maria Nascente, Milano (Italy); Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, (Spain); Riga Stradins University (RSU), Riga (Latvia)

Who may be able to join

  • COPD patients will be defined as a postbronchodilator ratio of FEV1/FEV <0.7. The severity of airflow limitation and phenotypes will be defined as described by the GOLD grading system, including Grade 2, 3 or 4.
  • Overlapped Asthma - COPD will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
  • Sex and age matched HC and AsP (bronchial asthma according to The Global Strategy for Asthma Management and Prevention 2018 from at least 6 months) will be recruited as controls.

Who cannot join

  • Exclusion criteria will be the combination with obstructive sleep apnea, cancer, MMSE<24, at least 4 weeks from the last acute exacerbation, cardiovascular, neurologic and kidney diseases, age<18
  • Bacterial or fungal oral infections in progress

Trial locations and contacts

5 sites in 4 countries.

5 sites in 4 countries

Italy2 sites, 1 recruiting
  • IRCCS Santa Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS

    Milan, 20148

    Paolo I Banfi, MD, 02 40308812 ext. +39, pabanfi@dongnocchi.it

    Marzia Bedoni, PhD, 0240308533 ext. +39, labion@dongnocchi.it

    Recruiting
  • University of Milano-Bicocca

    Milan

    Active, not recruiting

Other trials in Italy

Germany1 site
  • Geratherm Respiratory GmbH

    Bad Kissingen, 97688

    Active, not recruiting

Other trials in Germany

Latvia1 site, 1 recruiting
  • Riga Stradins University

    Riga, LV1007

    Madara Tirzīte, MD, 167409105 ext. +37, madara.tirzite@rsu.lv

    Recruiting

Other trials in Latvia

Spain1 site, 1 recruiting
  • Institut d'Investigacions Biomèdiques August Pi I Sunyer

    Barcelona, 08036

    Nestor Soler, MD, 2275549 ext. +34, nsoler@clinic.cat

    Recruiting

Other trials in Spain

About this study

Official title: Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management

Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and chronic lung syndrome that causes accelerated lung function decline and death in the 20% of cases. Mostly, the non-adherence to therapy contributes to symptoms increase, mortality, inability and therapies failure, highly influencing the management costs associated to COPD. The existing procedure of diagnosing COPD is effective and fast. The acute treatment and the subsequent disease management, instead, strictly depend on the currently long and complex process of identification of three factors: COPD phenotype, adherence to chosen therapy and probability of exacerbation events. The knowledge of these factors is needed by clinicians to stratify patients and personalise the therapies and rehabilitation procedures, to initiate an effective disease management. The application of Raman spectroscopy on saliva, representing an easy collectable and highly informative biofluid, has been already proposed for different infective, neurological and cancer diseases, with promising results in the diagnostic and monitoring fields. In this project, we propose the use of Deep Learning analysis of Raman spectra collected from COPD patient's saliva to be combined with other clinical data for the development of a system able to provide fast and sensitive information regarding COPD phenotypes, adherence and exacerbation risks. This will support clinicians to personalise COPD therapies and treatments, and to monitor their effectiveness.

Read the detailed description

The main goal of the project is to create and validate a new method based on the Raman spectroscopy (RS) analysis of saliva for the optimised and personalised management of patients with Chronic Obstructive Pulmonary disease (COPD). The combination of the clinical instrumental data with the RS-approach will increase the quality of the clinical practice through appropriate stratification of patients, i.e., early identification of COPD phenotypes, consequent attribution of precise therapies, assessment of potential exacerbation risk and adherence to therapy. By the integration of instrumental and RS measures with Artificial Intelligence (AI), patients' COPD phenotype will be predicted allowing to efficiently direct the resources of the health-care system. The feasibility of the work is corroborated by the use of a sensitive, fast and miniaturized RS, used by non-specialized personnel and for the creation of a point-of care (POC) on an accessible biofluid. The multidisciplinary approach in pre-clinical, clinical and big data management fields is achieved through collaboration of academy, clinical research and industry.

Starting from the unmet clinical need, CORSAI will build a close link between biomedical research, clinical research, data science towards the integration of PM into clinical practice and on ethical, legal, and social implications across the participating countries and beyond. The main objective is the collection of RS signals from the saliva of COPD patients, characterized for severity stages and phenotypes using GERA instruments, and corresponding CTRL and asthma patients (AsP). The creation and correlation of the dataset will lead to the accomplishment of specific objectives: I) Identification of the specific COPD, CTRL and AsP RF; II) Monitoring of therapy adherence through the drug signal in saliva; III) Definition of COPD phenotypes on the base of the RF correlated with instrumental GERA data; IV) Monitoring of the rehabilitation procedures and effects; V) Association of a high exacerbation risk to specific COPD patients; VI) Creation of a classification model from the RS database; VII) Application of high-performance computing for data analysis; VIII) Integration of the portable RS as POC. The novelty of CORSAI relies in the advanced methodology, brought to the bed side thanks to portable instruments. The minimal invasive procedure used for the saliva collection and the velocity for the Raman acquisition represent relevant advantages allowing the continuous monitoring of patients' adherence to therapy, and the contemporary discrimination of COPD phenotypes with high rate of exacerbation. The feasibility of the project is directly related to the biological sample and proposed technology, already tested in the clinical setting19: i)easy collection and storage of saliva fits the clinical scenario; ii) minimal sample preparation and portable device enable POC use by non-specialized personnel, with AI remote decision guidance.

SAMPLE COLLECTION: Saliva collection from all the selected subjects will be performed following the Salivette (SARSTEDT) manufacturer's instructions. To limit variability in salivary content not related to COPD, saliva will be obtained from all subjects at a fixed time, after an appropriate lag time from feeding and teeth brushing. Pre-analytical parameters (i.e. storage temperature and time between collection and processing), dietary and smoking habit will be properly recorded. Briefly, the swab will be removed, placed in the mouth and chewed for 60 seconds to stimulate salivation. Then the swab will be centrifuged for 2 minutes at 1,000 g to remove cells fragments and food debris. Collected samples will be stored at -80° C.

SAMPLE PROCESSING: For the Raman analysis, a drop of each sample will be casted on an aluminium foil in order to achieve the Surface Enhanced Raman Scattering (SERS).

DATA COLLECTION: SERS spectra will be acquired using an Aramis Raman microscope (Horiba Jobin-Yvon, France) equipped with a laser light source operating at 785 nm with laser power ranging from 25-100% (Max power 512 mW). Acquisition time between 10-30 seconds will be used. The instrument will be calibrated before each analysis using the reference band of silicon at 520.7 cm-1. Raman spectra will be collected from 35 points following a line-map from the edge to the centre of the drop. Spectra will be acquired in the region between 400 and 1600 cm-1 using a 50x objective (Olympus, Japan). Spectra resolution is about 1.2 cm-1. The software package LabSpec 6 (Horiba Jobin-Yvon, France) will be used for map design and the acquisition of spectra.

DATA PROCESSING: All the acquired spectra will be fit with a fourth-degree polynomial baseline and normalized by unit vector using the dedicated software LabSpec 6. The contribution of the substrate will be removed from each spectra. The statistical analysis to validate the method, will be performed using a multivariate analysis approach. Principal Component analysis (PCA) will be performed in order to reduce data dimensions and to evidence major trends. The first 20 resultant Principal Components (PCs) will be used in a classification model, Linear Discriminant Analysis (LDA), to discriminate the data maximizing the variance between the selected groups. The smallest number of PCs will be selected to prevent data overfitting. Leave-one-out cross-validation and confusion matrix test will be used to evaluate the method sensitivity, precision and accuracy of the LDA model. Mann-Whitney will be performed on PCs scores to verify the differences statistically relevant between the analysed groups. Correlation and partial correlation analysis will be performed using the Spearman's test, assuming as valid correlation only the coefficients with a p-value lower than 0.05. The statistical analysis will be performed using Origin2018 (OriginLab, USA).

DEEP LEARNING: The datasets will be analysed and processed using Deep Learning models with the aim to discover significant patterns that can be used to confirm and analyse trends and to develop predictions and decision support about the COPD stratification. Techniques of data augmentation and automatic hyperparameter optimization will be developed in order to enhance classification performances and improve generalization ability. In order to reach a tradeoff between predictive accuracy and interpretability, a class activation mapping (CAM)-based approach will be applied to visualize the active variables in the spectra in order to identify discriminative pattern to extract the most informative spectral features.

UNIMIB and GERA will implement an explanation mechanism to identify the active variables in whole spectrum and interpret the internal feature representations and data transformation pipeline of the CNN model. UNIMIB and GERA will integrate the various computational modules in a modular computational pipeline for patient-wise classification.

Being tested
Collection and Raman analysis of saliva for the database
Keywords
Raman Spectroscopy, COPD, Machine Learning, Biomarker
Medical subject headings
Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Collection and Raman analysis of saliva for the databaseProcedure or surgery

    Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model

Study groups in NCT04628962
Study groupRoleWhat they receive
Asthma-COPD Overlapped (aCOPD)50 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
Receives: Procedure: Collection and Raman analysis of saliva for the database
Non-Exacerbator COPD (neCOPD)50 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects
Receives: Procedure: Collection and Raman analysis of saliva for the database
frequent Excacerbator with Emphysema COPD (eeCOPD)50 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects
Receives: Procedure: Collection and Raman analysis of saliva for the database
frequent Excacerbator with chronic Bronchitis COPD (ebCOPD)50 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects
Receives: Procedure: Collection and Raman analysis of saliva for the database
Asthma patients (AST)200 subjects affected by asthma comparable by age and sex with the other recruited subjects
Receives: Procedure: Collection and Raman analysis of saliva for the database
Healthy subjects (CTRL)200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects
Receives: Procedure: Collection and Raman analysis of saliva for the database

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Identification of the salivary COPD Raman signature

    Raman spectroscopy will be used to analyse saliva of COPD patients, leading to the characterization of a specific COPD signature highlighting the differences between the one of asthma patients and healthy subjects. Using multivariate analysis, the possibility to create a classification model will be tested.

    Measured: Two years

  2. Characterization of the spectral differences of COPD patients

    Raman data will be interpreted comparing the signatures of the different experimental groups (COPD vs asthma vs healthy subjects), identifing the molecular classes responsible for the principal differences

    Measured: Two years

  3. Stratification of the 4 COPD phenotypes through the Raman signature

    An intra COPD class analysis will be performed, identifying the specific Raman signature of each phenotype considered in the study. The multivariate analysis will be performed evaluating the possibility to create a classification model able to perform a fast diagnosis based on the analysis of saliva

    Measured: Two years

  4. Monitoring of therapy adherence and effects

    Raman data will be correlated with the clinical parameters, identifying hidden trends and relationships between the two investigated factors. In particular, the effects of a full and missing therapy adherence will be evaluated in terms of changing in salivary Raman signatures

    Measured: Two years

  5. Determination of the exacerbation index

    The Raman signal associated with frequently exacerbator patients will be computed through linear discriminant analysis, obtaing coefficients related to the exacerbation event. In this way, a measurable parameter will be created in order to monitor and potentially forecast the exacerbation events

    Measured: Two years

  6. Application of a portable Raman spectrometer as Point of Care

    All the data, databases and classification models created in the previous outcomes will be integrated in a portable Raman instrument that will be applied directly on new patinets, in order to test the reliability of the methodology. At the same time, the new data will be used to train the model, increasing the discriminatory power in terms of accuracy, precision, sensitivity and specificity

    Measured: Three years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Nov 2020
  2. Study start1 Feb 2022
  3. Primary completion30 Nov 2023 (estimated)
  4. Study completion1 Jan 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04628962
Sponsor's protocol ID
FDG_RamanSaliva_COPD_CORSAI
Other IDs
ERAPERMED2021-383_CORSAI
Acronym
CORSAI
Status last verified
Feb 2022
First submitted
9 Nov 2020
Last updated
4 Apr 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Carlomagno C, Banfi PI, Gualerzi A, Picciolini S, Volpato E, Meloni M, Lax A, Colombo E, Ticozzi N, Verde F, Silani V, Bedoni M. Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. Sci Rep. 2020 Jun 23;10(1):10175. doi: 10.1038/s41598-020-67138-8.

    PubMed 32576912
  • Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018 Oct;93(10):1488-1502. doi: 10.1016/j.mayocp.2018.05.026.

    PubMed 30286833
  • Nikolaou V, Massaro S, Fakhimi M, Stergioulas L, Price D. COPD phenotypes and machine learning cluster analysis: A systematic review and future research agenda. Respir Med. 2020 Sep;171:106093. doi: 10.1016/j.rmed.2020.106093. Epub 2020 Jul 28.

    PubMed 32745966
  • Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012 Mar;48(3):86-98. doi: 10.1016/j.arbres.2011.10.007. Epub 2011 Dec 22. English, Spanish.

    PubMed 22196477

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 5 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Italy, Germany, Latvia, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Paolo I Banfi, MD (0240308812 ext. +39, pabanfi@dongnocchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Identification of the salivary COPD Raman signature (time frame: Two years). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04628962, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in